Vernalis PLC Block listing Interim Review (5737C)

TIDMVER

RNS Number : 5737C

Vernalis PLC

01 October 2018

BLOCK LISTING SIX MONTHLY RETURN AND BLOCK LISTING APPLICATION

VERNALIS PLC (the "Company")

1 October 2018

Vernalis plc (LSE: VER) provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:

 
 Name of applicant:                  Vernalis plc 
 Name of scheme(s):                  2007 Long Term Incentive Scheme 
                                      ("LTIP"); 2012 Value Builder Plan 
                                      ("VBP"); and 
                                      2016 Executive Incentive Plan 
                                      ("EIP") 
                                    -------------------------------------------------- 
 Period of return (from              From: 29/Mar/2018           To: 01/Oct/2018 
  / to): 
                                    --------------------------  ---------------------- 
 Balance of unallotted securities    Total of 2,149,159 Ordinary 1p 
  under scheme(s) from previous       Shares, split: 
  return:                              *    Under LTIP = 360,485 Ordinary 1p Shares 
 
 
                                       *    Under VBP = 1,788,674 Ordinary 1p Shares 
 
 
                                       *    Under EIP = nil Ordinary 1p Shares 
                                    -------------------------------------------------- 
 Plus: The amount by which           NIL 
  the block scheme(s) has 
  been increased or application 
  has been made to increase 
  since the date of the last 
  return (if any increase 
  has been applied for): 
                                    -------------------------------------------------- 
 Less: Number of securities          Total of 166,376 Ordinary 1p Shares, 
  issued/allotted under scheme(s)     split: 
  during period:                       *    Under LTIP = 39,405 Ordinary 1p Shares 
 
 
                                       *    Under VBP = 126,971 Ordinary 1p Shares 
                                    -------------------------------------------------- 
 Less: Number of securities          Total of 30,526 Ordinary 1p Shares: 
  forfeited under scheme(s)            *    Under LTIP = 30,526 Ordinary 1p Shares 
  during period: 
 
                                       *    Under VBP = nil Ordinary 1p Shares 
 
 
                                       *    Under EIP = nil Ordinary 1p Shares 
                                    -------------------------------------------------- 
 Equals: Balance under scheme(s)     Total of 1,952,257 Ordinary 1p 
  not yet issued/allotted             Shares, split: 
  at end of period:                    *    Under LTIP = 290,554 Ordinary 1p Shares 
 
 
                                       *    Under VBP = 1,661,703 Ordinary 1p Shares 
 
 
                                       *    Under EIP = nil Ordinary 1p Shares 
                                    -------------------------------------------------- 
 Number and class of securities       No. of Ordinary   Date on which Shares 
  originally admitted and               1p Shares         were Admitted to 
  the date of admission (including                        Trading 
  any additions):                      350,000           6 November 2013, 
                                                          plus 
                                                        --------------------- 
                                       1,049,317         12 May 2014, plus 
                                                        --------------------- 
                                       1,058,184         12 May 2015, plus 
                                                        --------------------- 
                                       1,638,364         30 September 2015, 
                                                          plus 
                                                        --------------------- 
                                       1,189,296         1 April 2016, plus 
                                                        --------------------- 
                                       499,612           31 March 2017, plus 
                                                        --------------------- 
                                       1,788,674         2 October 2017, plus 
                                                        --------------------- 
                                       95,654            5 April 2018 
                                                        --------------------- 
                                    -------------------------------------------------- 
 

-- ends --

Enquiries:

 
 Vernalis plc:                              [phone] 
 Ian Garland, Chief Executive Officer 
  David Mackney, Chief Financial Officer 
 Canaccord plc (Nominated Adviser and 
  Broker):                                  [phone] 
 Henry Fitzgerald-O'Connor 
  Emma Gabriel 
 Evercore (Financial Adviser):              [phone] 
 Julian Oakley 
  Alan Beirne 
 

Notes to Editors

About Vernalis

Vernalis is a revenue generating, pharmaceutical company with significant expertise in drug development. The Group has two approved products: Moxatag(R) , a once-daily formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older; and frovatriptan for the acute treatment of migraine. Vernalis has also nine programmes in its NCE development pipeline in addition to significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Daiichi Sankyo, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis and Servier.

For further information about Vernalis, please visit www.vernalis.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

BLRMBBJTMBAMBJP

(END) Dow Jones Newswires

October 01, 2018 09:57 ET (13:57 GMT)